



Collaborate Meeting

Mayo Clinic

Trondheim and Bergen Renal Research Groups/

Norwegian Society of Nephrology

Scandic Nidelven, Trondheim, Sept 11st – 13th 2019

WEDNESDAY Sept.11th

19.00 – 19.10	<i>Welcome</i>	Knut Aasarød
19.10-19.40	Membranous Nephropathy: time for a paradigm shift?	Fernando Fervenza, Mayo

Thursday SEPT 12th

	<i>Clinical nephrology I</i>	
08.30-09.00	Structural and functional changes in the aging kidney	Andrew Rule, Mayo
09.00 - 9.30	GFR in healthy ageing. The Tromsø study	Bjørn Odvar Eriksen, Tromsø
09.30-10.00	Nutritional interventions for prevention of accelerated aging and fibrosis in the kidney	Ivar Anders Eide, AHUS, Oslo
10.00-10.30	Coffee break/ Exhibitions	
	<i>Transplantation</i>	
10.30 - 11.00	Recurrent glomerular diseases after kidney transplantation.	Fernando G Cosio, Mayo
11.00-11.30	Revamping Banff: A critical reappraisal of the current approach to reading kidney transplant biopsies	Mark D Stegall, Mayo
11.30-12.30	Lunch	
12.30-13.00	Alloantibody: Current status of the basic biology and clinical applications	Mark D Stegall, Mayo
13.00-13.30	Post-transplant diabetes mellitus – new insight into pathogenesis and treatment	Trond Jenssen, RH Oslo
13.30-14.00	Coffee Break/Exhibitions	
	<i>ANCA-associated Vasculitis</i>	
14.00-14.30	Clinical approach to pulmonary involvement in ANCA-associated vasculitis: Why should nephrologists care?	Ulrich Specks, Mayo

14.30 -14.50	PRO: There is still a place for PE in ANCA-associated vasculitis.	Wladimir Szpirt, Copenhagen
14.50-15.10	CON: There is no place for PE in ANCA-associated vasculitis.	Ulrich Specks, Mayo
15.10 – 15.30	Discussion	
15.30 -16.00	Coffee Break/ Exhibitions	
	<i>Clinical nephrology II</i>	
16.00 -16.30	Update on polycystic kidney disease.	Vicente Torres, Mayo
16.30 –17.00	Kidney tubule health and risk of CKD progression and cardiovascular disease	Joachim Ix, UCSD
17.00-17.30	Long-term renal outcomes after preeclampsia	Andrea G Kattah
17.30-1745	Coffee Break/ Exhibitions	
17.45-18.15	The effect of exercise on kidney function	Knut Asbjørn R Langlo, Trondheim
18.15-18.45	Adherence in hypertension	Aud Høiegggen, Ullevål, Oslo
18.45 -19.15	Focal segmental glomerulosclerosis update: What clinicians and patients should know	Fernando Fervenza, Mayo
20.00	Dinner	

FRIDAY SEPT 13th

	<i>Clinical nephrology III</i>	
08.30-09.00	Diabetes mellitus related nephropathy: The pathophysiology of excessive proteinuria	Eddie Greene, Mayo
09.00-09.30	Membranous and Minimal Change Nephropathy: Novel Insights from Glomerular RNA Sequencing	Øystein Eikrem, Bergen
09.30-10.00	Steroid therapy for IgA-nephropathy. A conundrum of safety and efficacy	Richard Glassock UCLA
10.00 – 10.30	Coffee Break/ Exhibitions	
10.30 -11.00	Crystal disorders of the kidney and their association with systemic disease	Dawn S Milliner Mayo
11.00-11.30	Rituximab as an immunosuppressive agent in renal disease: Efficacy and safety.	Richard J Glassock UCLA
11.30-12.00	aGBM-disease: Current treatment strategy and some future possibilities	Mårten Segelmark, Lund
12.00 – 12.30	Monoclonal gammopathy of renal significance (MGRS), what does the future hold?	Ladan Zand Mayo